MX362591B - Uso de antagonistas de il-17. - Google Patents
Uso de antagonistas de il-17.Info
- Publication number
- MX362591B MX362591B MX2013005060A MX2013005060A MX362591B MX 362591 B MX362591 B MX 362591B MX 2013005060 A MX2013005060 A MX 2013005060A MX 2013005060 A MX2013005060 A MX 2013005060A MX 362591 B MX362591 B MX 362591B
- Authority
- MX
- Mexico
- Prior art keywords
- rheumatoid arthritis
- antagonists
- methods
- treating rheumatoid
- antibody
- Prior art date
Links
- 206010039073 rheumatoid arthritis Diseases 0.000 title abstract 4
- 239000005557 antagonist Substances 0.000 title abstract 2
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 102000004554 Interleukin-17 Receptors Human genes 0.000 abstract 1
- 108010017525 Interleukin-17 Receptors Proteins 0.000 abstract 1
- 206010003246 arthritis Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 229960004540 secukinumab Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicinal Preparation (AREA)
Abstract
La invención se refiere a un artículo para IL-17 para usarse en el tratamiento de un paciente con espondilitis anquilosantes (AS), en donde el anticuerpo está adaptado para ser administrable a través de: a) cinco dosis subcutáneas de aproximadamente 150 mg a aproximadamente 300 mg del anticuerpo para IL-17, cada una de las cinco dosis adaptada para ser administrable semanalmente; y b) en adelante, una dosis subcutánea de aproximadamente 150 mg a aproximadamente 300 mg del anticuerpo para IL-17 cada 4 semanas, en donde el anticuerpo para IL-17 tiene una KD de aproximadamente aproximadamente 100 a 200 pM, medida por Biacore, y en donde dicho anticuerpo para IL-17 comprende: 1) un dominio VH de inmunoglobulina que comprende la secuencia de aminoácidos SEQ ID NO: 8 y un dominio VL de inmunoglobulina que comprende la secuencia de aminoácidos SEQ ID NO: 10; ii) un dominio VH de inmunoglobulina que comprende las regiones hipervariables como las SEQ ID NO: 1, SEQ ID NO; 2, y SEQ ID NO: 3, y un dominio VL de inmunoglobulina que comprende las regiones hipervarialbes como las SEQ ID NO: 4, SEQ ID NO: 5 y SEQ ID NO: 6; o iii) un domino VH de inmunoglobulina que comprende las regiones hipervariables como las SEQ ID NO: 11, SEQ ID NO: 12, y SEQ ID NO: 13, y un dominio VL de inmunoglobulina que comprende las regiones hIpervariables las SEQ ID NO: 4, SEQ ID NO: 5 y SEQ ID NO: 6.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41053310P | 2010-11-05 | 2010-11-05 | |
| PCT/EP2011/069476 WO2012059598A2 (en) | 2010-11-05 | 2011-11-04 | Methods of treating rheumatoid arthritis using il-17 antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2013005060A MX2013005060A (es) | 2013-06-28 |
| MX362591B true MX362591B (es) | 2019-01-25 |
Family
ID=44906168
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013005060A MX362591B (es) | 2010-11-05 | 2011-11-04 | Uso de antagonistas de il-17. |
Country Status (27)
| Country | Link |
|---|---|
| US (9) | US9744234B2 (es) |
| EP (6) | EP3111954B1 (es) |
| JP (7) | JP2014503482A (es) |
| KR (5) | KR20140008305A (es) |
| CN (2) | CN103189074A (es) |
| AU (1) | AU2011325134B2 (es) |
| BR (1) | BR112013011176A2 (es) |
| CA (2) | CA2813849C (es) |
| CL (1) | CL2013001213A1 (es) |
| CY (1) | CY1121802T1 (es) |
| DE (1) | DE20187001T1 (es) |
| DK (1) | DK3111954T3 (es) |
| ES (2) | ES2733712T3 (es) |
| HR (1) | HRP20191162T1 (es) |
| HU (1) | HUE044038T2 (es) |
| IL (4) | IL311014A (es) |
| LT (1) | LT3111954T (es) |
| MA (1) | MA34647B1 (es) |
| MX (1) | MX362591B (es) |
| PL (1) | PL3111954T3 (es) |
| PT (1) | PT3111954T (es) |
| RU (1) | RU2582937C2 (es) |
| SG (2) | SG189138A1 (es) |
| SI (1) | SI3111954T1 (es) |
| TR (1) | TR201909531T4 (es) |
| TW (3) | TWI604851B (es) |
| WO (1) | WO2012059598A2 (es) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20130080790A (ko) | 2010-05-20 | 2013-07-15 | 아블린쓰 엔.브이. | Ｈｅｒ３와 관련된 생물학적 물질들 |
| HUE044038T2 (hu) | 2010-11-05 | 2019-09-30 | Novartis Ag | Spondilitisz ankilopoetika kezelési eljárásai anti-IL-17 alkalmazásával |
| UA117218C2 (uk) | 2011-05-05 | 2018-07-10 | Мерк Патент Гмбх | Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f |
| CN116063509A (zh) | 2011-10-11 | 2023-05-05 | 维埃拉生物股份有限公司 | Cd40l-特异性tn3-衍生的支架及其使用方法 |
| WO2013116682A1 (en) | 2012-02-02 | 2013-08-08 | Ensemble Therapeutics Corporation | Macrocyclic compounds for modulating il-17 |
| US20140004131A1 (en) | 2012-05-04 | 2014-01-02 | Novartis Ag | Antibody formulation |
| WO2014155278A2 (en) | 2013-03-26 | 2014-10-02 | Novartis Ag | Methods of treating autoimmune diseases using il-17 antagonists |
| CA2928317A1 (en) | 2013-10-22 | 2015-04-30 | Novimmune S.A. | Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of tlr4 ligands and other biomarkers |
| JP2017508446A (ja) * | 2014-01-28 | 2017-03-30 | 北京韓美薬品有限公司 | 二機能性融合タンパク質及びその製造方法並びに使用 |
| JP6648038B2 (ja) | 2014-05-13 | 2020-02-14 | メディミューン リミテッド | 非小細胞肺がんを治療するための抗ｂ７−ｈ１および抗ｃｔｌａ−４抗体 |
| EP3142645A4 (en) | 2014-05-15 | 2017-12-27 | Rani Therapeutics, LLC | Pharmaceutical compositions and methods for fabrication of solid masses comprising polypeptides and/or proteins |
| US11548940B2 (en) | 2014-05-15 | 2023-01-10 | Rani Therapeutics, Llc | Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| FR3021976B1 (fr) * | 2014-06-06 | 2018-11-02 | Hospices Civils De Lyon | Marqueur biologique permettant d'evaluer le niveau pro-inflammatoire dependant de la contribution fonctionnelle de l'il-17 chez un individu |
| US20160002326A1 (en) * | 2014-06-10 | 2016-01-07 | Abbvie Inc. | Compositions and methods for treating rheumatoid arthritis |
| NL2013007B1 (en) * | 2014-06-16 | 2016-07-05 | Ablynx Nv | Methods of treating TTP with immunoglobulin single variable domains and uses thereof. |
| PL3191120T3 (pl) * | 2014-09-10 | 2024-08-26 | Novartis Ag | Zastosowanie antagonistów il-17 do hamowania postępu uszkodzeń strukturalnych u pacjentów z łuszczycowym zapaleniem stawów |
| MX2017004983A (es) * | 2014-10-22 | 2017-11-13 | Armo Biosciences Inc | Metodos para usar interleucina 10 para tratar enfermedades y trastornos. |
| AR103173A1 (es) * | 2014-12-22 | 2017-04-19 | Novarits Ag | Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17 |
| US10500273B2 (en) | 2015-03-02 | 2019-12-10 | 180 Therapeutics Lp | Method of treating a localized fibrotic disorder using an IL-33 antagonist |
| EP3167892A1 (en) | 2015-11-10 | 2017-05-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for preventing or treating imflammatory bowel diseases |
| RU2728710C2 (ru) * | 2015-10-19 | 2020-07-30 | Новартис Аг | Способы лечения нерентгенографического аксиального спондилоартрита, используя антагонисты интерлейкина-17 (il-17) |
| AU2017316513A1 (en) * | 2016-08-23 | 2019-03-28 | Csl Behring Gmbh | Method of preventing acute attacks of hereditary angioedema associated with C1 esterase inhibitor deficiency |
| JP2021501752A (ja) * | 2017-11-02 | 2021-01-21 | ノバルティス アーゲー | インターロイキン−１７（ｉｌ−１７）アンタゴニストを使用して腱障害を治療する方法 |
| GB201719447D0 (en) * | 2017-11-23 | 2018-01-10 | Ucb Biopharma Sprl | Pharmaceutical composition |
| EP3790576A1 (en) * | 2018-05-09 | 2021-03-17 | Novartis Ag | Use of canakinumab |
| JP2022502412A (ja) * | 2018-09-26 | 2022-01-11 | ビエラ バイオ インコーポレイテッド | Ｃｄ４０ｌアンタゴニスト及びその使用 |
| KR20210119457A (ko) * | 2019-01-22 | 2021-10-05 | 에프. 호프만-라 로슈 아게 | 브루톤 티로신 키나제 억제제를 이용한 류마티스 관절염, 만성 자발성 두드러기 및 전신 홍반 루푸스의 치료 방법 |
| KR20210114989A (ko) | 2019-02-18 | 2021-09-24 | 일라이 릴리 앤드 캄파니 | 치료 항체 제제 |
| KR102169901B1 (ko) * | 2019-05-17 | 2020-10-26 | 연세대학교 산학협력단 | Dna 메틸화를 이용한 면역 항암 요법의 치료 반응에 관한 정보 제공 방법 및 이를 이용한 키트 |
| CN110179746A (zh) * | 2019-05-17 | 2019-08-30 | 通化东宝生物科技有限公司 | 一种稳定的苏金单抗注射剂及其制备方法 |
| AR121183A1 (es) | 2019-11-19 | 2022-04-27 | Novartis Ag | Métodos de tratamiento de la nefritis lúpica con antagonistas de interleucina-17 (il-17) |
| CN112915201B (zh) * | 2019-12-06 | 2023-06-27 | 珠海市丽珠单抗生物技术有限公司 | 包含抗il-17抗体的液体制剂 |
| WO2021146850A1 (en) * | 2020-01-20 | 2021-07-29 | Tsinghua University | A critical role of febrile temperature in regulating interleukin (il) -17 producing cells via smad4 |
| US20240101659A1 (en) * | 2020-11-25 | 2024-03-28 | Dr. Reddy’S Laboratories Limited | Stable therapeutic protein formulation and methods of making the same |
| WO2022144023A1 (zh) * | 2021-01-04 | 2022-07-07 | 江苏恒瑞医药股份有限公司 | 抗il-17抗体治疗自身免疫性疾病和炎症的方法 |
| WO2022184114A1 (zh) * | 2021-03-03 | 2022-09-09 | 苏州盛迪亚生物医药有限公司 | 抗il-17抗体治疗自身免疫性疾病和炎症的方法 |
| KR102339377B1 (ko) * | 2021-03-29 | 2021-12-13 | 김지혜 | 사용자 맞춤형 문화 예술 컨텐츠 제공 방법 및 장치 |
| EP4359438A1 (en) * | 2021-06-21 | 2024-05-01 | Bristol-Myers Squibb Company | Use of sucrose, mannitol and glycine to reduce reconstitution time of high concentration lyophilized biologics drug products |
| CN114306594A (zh) * | 2021-12-21 | 2022-04-12 | 华中科技大学同济医学院附属协和医院 | 地舒单抗在制备治疗膝关节骨性关节炎的药物中的应用 |
| EP4406553A1 (en) | 2023-01-27 | 2024-07-31 | Fresenius Kabi Deutschland GmbH | Stable secukinumab biopharmaceutical composition |
| WO2024156841A1 (en) | 2023-01-27 | 2024-08-02 | Fresenius Kabi Deutschland Gmbh | Biopharmaceutical composition |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0565233A (ja) | 1991-03-08 | 1993-03-19 | Mitsui Toatsu Chem Inc | モノクローナル抗体含有凍結乾燥製剤 |
| US5250442A (en) * | 1993-04-08 | 1993-10-05 | Orestes Cabezas | Method of treating rheumatoid arthritis using tetracycline |
| US6309636B1 (en) * | 1995-09-14 | 2001-10-30 | Cancer Research Institute Of Contra Costa | Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides |
| EP0852951A1 (de) | 1996-11-19 | 1998-07-15 | Roche Diagnostics GmbH | Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern |
| US20050147609A1 (en) | 1998-05-15 | 2005-07-07 | Genentech, Inc. | Use of anti-IL-17 antibody for the treatment of cartilage damaged by osteoarthritis |
| JP2000186046A (ja) | 1998-10-14 | 2000-07-04 | Snow Brand Milk Prod Co Ltd | 慢性関節リウマチ治療剤及び診断方法 |
| NZ512122A (en) | 1998-11-27 | 2003-12-19 | Darwin Discovery Ltd | Compositions and methods for increasing bone mineralization |
| US20040009535A1 (en) | 1998-11-27 | 2004-01-15 | Celltech R&D, Inc. | Compositions and methods for increasing bone mineralization |
| EP1409018B1 (en) | 2001-07-25 | 2010-01-06 | Facet Biotech Corporation | Stable lyophilized pharmaceutical formulation the igg antibody daclizumab |
| EP1455822A4 (en) | 2001-11-09 | 2004-12-29 | Centocor Inc | LYOPHILIZED MONOCLONAL ANTIBODY COMPOSITIONS |
| JP4662714B2 (ja) | 2002-03-01 | 2011-03-30 | セルテック アール アンド ディー インコーポレイテッド | 骨密度を増減させる方法 |
| AU2003276430A1 (en) | 2002-06-14 | 2003-12-31 | Stowers Institute For Medical Research | Wise/sost nucleic acid sequences and amino acid sequences |
| US6974701B2 (en) | 2003-03-21 | 2005-12-13 | Hemovations, Llc | Erythrocyte sedimentation rate (ESR) test measurement instrument of unitary design and method of using the same |
| EA015166B1 (ru) | 2003-06-16 | 2011-06-30 | Ю-Си-Би Мэньюфэкчуринг, Инк. | Иммуногенные пептиды склеростина (sost), индуцирующие образование специфических антител |
| US8461155B2 (en) | 2003-09-22 | 2013-06-11 | University Of Connecticut | Sclerostin and the inhibition of WNT signaling and bone formation |
| GB0417487D0 (en) * | 2004-08-05 | 2004-09-08 | Novartis Ag | Organic compound |
| JP3936365B2 (ja) | 2004-09-14 | 2007-06-27 | ソニーケミカル＆インフォメーションデバイス株式会社 | 機能素子実装モジュール及びその製造方法 |
| KR100989280B1 (ko) | 2005-03-08 | 2010-10-20 | 파마시아 앤드 업존 캄파니 엘엘씨 | 항-ｃｔｌａ-4 항체 조성물 |
| US8003108B2 (en) | 2005-05-03 | 2011-08-23 | Amgen Inc. | Sclerostin epitopes |
| US7592429B2 (en) | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
| EP1957474A4 (en) | 2005-11-04 | 2011-08-24 | Harvard College | SYNTHESIS OF FTFZ INHIBITORS |
| MY149159A (en) | 2005-11-15 | 2013-07-31 | Hoffmann La Roche | Method for treating joint damage |
| WO2007074880A1 (ja) | 2005-12-28 | 2007-07-05 | Chugai Seiyaku Kabushiki Kaisha | 抗体含有安定化製剤 |
| WO2007117749A2 (en) | 2006-01-31 | 2007-10-18 | Novartis Ag | Il-17 antagonistic antibodies fpr treating cancer |
| TW200815469A (en) | 2006-06-23 | 2008-04-01 | Astrazeneca Ab | Compounds |
| WO2008030611A2 (en) | 2006-09-05 | 2008-03-13 | Medarex, Inc. | Antibodies to bone morphogenic proteins and receptors therefor and methods for their use |
| TW200826974A (en) | 2006-09-07 | 2008-07-01 | Kirin Pharma Kk | Stable lyophilized pharmaceutical preparation comprising antibody |
| US7767206B2 (en) | 2006-10-02 | 2010-08-03 | Amgen Inc. | Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto |
| CN101541833B (zh) * | 2006-10-02 | 2014-01-29 | 麒麟-安姆根有限公司 | Il-17受体a抗原结合蛋白质 |
| EP2423226A3 (en) | 2006-11-10 | 2012-05-30 | Amgen Inc. | Antibody-based diagnostics and therapeutics |
| EP2460828A3 (en) | 2006-11-10 | 2012-08-08 | UCB Pharma, S.A. | Antibodies and diagnostics |
| EA200901031A1 (ru) | 2007-02-02 | 2010-04-30 | Новартис Аг | Модуляторы склеростин-связывающих партнеров для лечения костных расстройств |
| DK2131860T3 (da) | 2007-03-20 | 2014-01-13 | Lilly Co Eli | Anti-sclerostin-antistoffer |
| EA200970880A1 (ru) | 2007-03-22 | 2010-02-26 | Имклоун Элэлси | Стабильные композиции на основе антител |
| CN101678103A (zh) * | 2007-03-30 | 2010-03-24 | 米迪缪尼股份有限公司 | 抗体制剂 |
| JP5237366B2 (ja) * | 2007-06-20 | 2013-07-17 | メルク・シャープ・アンド・ドーム・コーポレーション | 炎症性関節疾患に対する抗ｉｌ−１７ａ治療のための関節破壊のバイオマーカー |
| US7720605B2 (en) | 2007-06-22 | 2010-05-18 | Weyerhaeuser Nr Company | Identifying vegetation attributes from LiDAR data |
| CL2008002775A1 (es) | 2007-09-17 | 2008-11-07 | Amgen Inc | Uso de un agente de unión a esclerostina para inhibir la resorción ósea. |
| AR068767A1 (es) | 2007-10-12 | 2009-12-02 | Novartis Ag | Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina |
| US20110044978A1 (en) | 2007-12-14 | 2011-02-24 | Amgen Inc. | Method for treating bone fracture |
| EP2297209A4 (en) | 2008-06-03 | 2012-08-01 | Abbott Lab | IMMUNOGLOBULINS WITH TWO VARIABLE DOMAINS AND USES THEREOF |
| MX2010014574A (es) | 2008-07-08 | 2011-04-27 | Abbott Lab | Inmunoglobulinas de dominio variable dual para prostaglandina e2 y usos de las mismas. |
| NZ591484A (en) | 2008-09-29 | 2012-09-28 | Roche Glycart Ag | Antibodies against human il 17 and uses thereof |
| US20110293605A1 (en) | 2008-11-12 | 2011-12-01 | Hasige Sathish | Antibody formulation |
| FR2938547B1 (fr) | 2008-11-14 | 2012-11-16 | Total Raffinage Marketing | Liant synthetique clair |
| WO2010065491A2 (en) | 2008-12-01 | 2010-06-10 | Carolus Therapeutics, Inc. | Methods of treating inflammatory disorders |
| CN102781470B (zh) | 2009-03-05 | 2016-01-20 | Abbvie公司 | Il-17结合蛋白 |
| HUE044038T2 (hu) * | 2010-11-05 | 2019-09-30 | Novartis Ag | Spondilitisz ankilopoetika kezelési eljárásai anti-IL-17 alkalmazásával |
| TW201307845A (zh) | 2010-12-13 | 2013-02-16 | Novartis Ag | 預測方法及利用ｉｌ－１７拮抗劑治療關節炎的方法 |
-
2011
- 2011-11-04 HU HUE16163440A patent/HUE044038T2/hu unknown
- 2011-11-04 JP JP2013537154A patent/JP2014503482A/ja active Pending
- 2011-11-04 ES ES16163440T patent/ES2733712T3/es active Active
- 2011-11-04 EP EP16163440.7A patent/EP3111954B1/en not_active Revoked
- 2011-11-04 DE DE20187001.1T patent/DE20187001T1/de active Pending
- 2011-11-04 RU RU2013125775/15A patent/RU2582937C2/ru active
- 2011-11-04 PT PT16163440T patent/PT3111954T/pt unknown
- 2011-11-04 SG SG2013023064A patent/SG189138A1/en unknown
- 2011-11-04 KR KR1020137011539A patent/KR20140008305A/ko not_active Application Discontinuation
- 2011-11-04 TW TW100140410A patent/TWI604851B/zh active
- 2011-11-04 BR BR112013011176-3A patent/BR112013011176A2/pt not_active IP Right Cessation
- 2011-11-04 MX MX2013005060A patent/MX362591B/es active IP Right Grant
- 2011-11-04 DK DK16163440.7T patent/DK3111954T3/da active
- 2011-11-04 CN CN2011800529537A patent/CN103189074A/zh active Pending
- 2011-11-04 TW TW105142587A patent/TWI618543B/zh active
- 2011-11-04 US US13/877,585 patent/US9744234B2/en active Active
- 2011-11-04 EP EP22180976.7A patent/EP4116325A1/en active Pending
- 2011-11-04 PL PL16163440T patent/PL3111954T3/pl unknown
- 2011-11-04 SI SI201131750T patent/SI3111954T1/sl unknown
- 2011-11-04 AU AU2011325134A patent/AU2011325134B2/en not_active Expired - Fee Related
- 2011-11-04 EP EP21180656.7A patent/EP3912640A1/en active Pending
- 2011-11-04 KR KR1020187034385A patent/KR20180129991A/ko not_active Application Discontinuation
- 2011-11-04 EP EP20187001.1A patent/EP3757126A1/en active Pending
- 2011-11-04 WO PCT/EP2011/069476 patent/WO2012059598A2/en active Application Filing
- 2011-11-04 KR KR1020187004058A patent/KR20180019247A/ko active Search and Examination
- 2011-11-04 CA CA2813849A patent/CA2813849C/en active Active
- 2011-11-04 KR KR1020167014431A patent/KR20160067984A/ko active Search and Examination
- 2011-11-04 EP EP11778903.2A patent/EP2635303A2/en not_active Withdrawn
- 2011-11-04 LT LTEP16163440.7T patent/LT3111954T/lt unknown
- 2011-11-04 TW TW104103341A patent/TWI616204B/zh active
- 2011-11-04 TR TR2019/09531T patent/TR201909531T4/tr unknown
- 2011-11-04 IL IL311014A patent/IL311014A/en unknown
- 2011-11-04 KR KR1020157003096A patent/KR20150020734A/ko not_active Application Discontinuation
- 2011-11-04 ES ES20187001T patent/ES2804624T1/es active Pending
- 2011-11-04 CA CA3116725A patent/CA3116725C/en active Active
- 2011-11-04 EP EP19162707.4A patent/EP3542820A1/en not_active Withdrawn
- 2011-11-04 CN CN201510199026.8A patent/CN104800844A/zh active Pending
- 2011-11-04 SG SG10201505624VA patent/SG10201505624VA/en unknown
-
2013
- 2013-03-18 IL IL225309A patent/IL225309B/en active IP Right Grant
- 2013-05-03 CL CL2013001213A patent/CL2013001213A1/es unknown
- 2013-05-03 MA MA35873A patent/MA34647B1/fr unknown
-
2015
- 2015-11-30 JP JP2015232562A patent/JP6049843B2/ja active Active
-
2016
- 2016-07-14 JP JP2016139469A patent/JP6250109B2/ja active Active
-
2017
- 2017-07-20 US US15/654,854 patent/US10363307B2/en active Active
- 2017-11-21 JP JP2017223669A patent/JP6515168B2/ja active Active
-
2018
- 2018-10-24 IL IL262559A patent/IL262559B/en unknown
-
2019
- 2019-04-12 JP JP2019076324A patent/JP2019142912A/ja active Pending
- 2019-06-12 US US16/439,423 patent/US20190307880A1/en not_active Abandoned
- 2019-06-26 HR HRP20191162TT patent/HRP20191162T1/hr unknown
- 2019-07-03 CY CY20191100708T patent/CY1121802T1/el unknown
-
2020
- 2020-03-19 US US16/824,613 patent/US11534491B2/en active Active
- 2020-12-18 US US17/127,758 patent/US20210128726A1/en not_active Abandoned
-
2021
- 2021-02-02 US US17/165,729 patent/US20210177966A1/en not_active Abandoned
- 2021-03-01 JP JP2021031383A patent/JP2021104995A/ja active Pending
- 2021-04-25 IL IL282625A patent/IL282625A/en unknown
- 2021-12-08 US US17/545,894 patent/US20220193234A1/en active Pending
-
2022
- 2022-10-21 US US18/048,797 patent/US20230293683A1/en active Pending
- 2022-12-02 US US18/061,221 patent/US20230346926A1/en active Pending
-
2023
- 2023-05-23 JP JP2023084472A patent/JP2023109910A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX362591B (es) | Uso de antagonistas de il-17. | |
| MX356279B (es) | Métodos para el tratamiento de soriasis usando antagonistas de il-17. | |
| BR112013021863A2 (pt) | anticorpos anti-receptor il-6 e métodos de uso | |
| MX2021015309A (es) | Composiciones para el tratamiento de la artritis reumatoide y metodos para su uso. | |
| MX2023000079A (es) | Composiciones farmaceuticas que comprenden un antagonista de il-4r para usarse en el tratamiento de sinusitis cronica con polipos nasales. | |
| AU2014284235B2 (en) | Methods for treating nasal polyposis by administering an IL-4R antagonist | |
| UA116873C2 (uk) | Антитіло, яке зв'язується з ox40 | |
| MY164755A (en) | Antagonist anti-il-7 receptor antibodies and methods | |
| EA201290254A1 (ru) | Антагонисты il-17a | |
| WO2011154139A3 (en) | Gene expression markers for predicting response to interleukin-6 receptor-inhibiting monoclonal antibody drug treatment | |
| MX2009008608A (es) | Anticuerpos monoclonales anti-cxcl13. | |
| MX369148B (es) | Agentes de unión kir3dl2. | |
| EA201300256A1 (ru) | Антитела к рецептору эпидермального фактора роста-3 (her3) | |
| CY1113640T1 (el) | Μεθοδοι για την θεραπευτικη αγωγη ρευματοειδους αρθριτιδας | |
| MY175878A (en) | Anti-il-17 antibodies, a method for producing and using thereof | |
| UA113623C2 (uk) | Моноклональне антитіло проти інгібітору шляху тканинного фактора (tfpi) | |
| EA201500316A1 (ru) | Антагонисты толл-подобного рецептора 3 | |
| WO2012103360A3 (en) | Wnt compositions and methods of use thereof | |
| WO2012009631A8 (en) | Humanized antibodies targeting the ec1 domain of cadherin-11 and related compositions and methods | |
| TN2012000466A1 (en) | Humanized anti cxcr4 antibodies for the treatment of cancer | |
| EA201171307A1 (ru) | Антагонисты толл-подобного рецептора 3 | |
| EA201390537A1 (ru) | Антигенсвязывающие белки, связывающиеся с онкостатином м (osm) | |
| EA201490623A1 (ru) | Антагонисты толл-подобного рецептора 3 для лечения метаболических и сердечно-сосудистых заболеваний | |
| IN2014DN07875A (es) | ||
| TN2013000144A1 (en) | Methods of treating rheumatoid arthuritis using il-17 antagonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |